arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Regencell Bioscience Holdings Ltd

RGC

$5.41 ▼ -0.02 (-0.37%) at close

8 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Regencell Bioscience Holdings Ltd faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.7B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -61.3% ↘

FCF / Share $-0.01 ↗

Trailing P/E —

Price / Book 550.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-3.58M

↑ +16.7% —

FCF / Share Free cash flow per share

$-0.01

↑ +18.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Jun 30, 2025 20-F ↗	FY 2024 Jun 30, 2024 20-F ↗	FY 2023 Jun 30, 2023 20-F ↗	FY 2022 Jun 30, 2022 20-F ↗	FY 2021 Jun 30, 2021 20-F ↗	FY 2020 Jun 30, 2020 20-F ↗	FY 2019 Jun 30, 2019 20-F ↗	FY 2018 Jun 30, 2018 20-F ↗
EPS Growth YoY (%)	17.2% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	-22.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	346.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	16.7% Good ↑ Good Improving Year-over-year change in net income	26.7% Excellent ↑ Excellent Improving Year-over-year change in net income	21.1% Good ↑ Good Improving Year-over-year change in net income	-452.9% Weak ↓ Weak Declining Year-over-year change in net income	-65.8% Weak Weak Year-over-year change in net income	-107.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	18.5% Good ↑ Good Improving Year-over-year change in free cash flow	97.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	18.8% Good Good Year-over-year change in free cash flow	-515.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Jun 30, 2025 20-F ↗	FY 2024 Jun 30, 2024 20-F ↗	FY 2023 Jun 30, 2023 20-F ↗	FY 2022 Jun 30, 2022 20-F ↗	FY 2021 Jun 30, 2021 20-F ↗	FY 2020 Jun 30, 2020 20-F ↗	FY 2019 Jun 30, 2019 20-F ↗	FY 2018 Jun 30, 2018 20-F ↗
FCF / Net Income (x)	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Jun 30, 2025 20-F ↗	FY 2024 Jun 30, 2024 20-F ↗	FY 2023 Jun 30, 2023 20-F ↗	FY 2022 Jun 30, 2022 20-F ↗	FY 2021 Jun 30, 2021 20-F ↗	FY 2020 Jun 30, 2020 20-F ↗	FY 2019 Jun 30, 2019 20-F ↗	FY 2018 Jun 30, 2018 20-F ↗
Return on Invested Capital (%)	-61.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	27.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	24.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	16.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-65.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-49.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-42.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-406.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-158.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-73.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-715%)	-52.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-536%)	-48.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-507%)	-43.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-464%)	33.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+181%)	30.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+155%)	21.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+77%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Jun 30, 2025 20-F ↗	FY 2024 Jun 30, 2024 20-F ↗	FY 2023 Jun 30, 2023 20-F ↗	FY 2022 Jun 30, 2022 20-F ↗	FY 2021 Jun 30, 2021 20-F ↗	FY 2020 Jun 30, 2020 20-F ↗	FY 2019 Jun 30, 2019 20-F ↗	FY 2018 Jun 30, 2018 20-F ↗
Net Debt (USD)	—	—	—	—	$-59.41K	$-386.98K	$-243.31K	$-153.30K

📊 What does each share earn? 5 metrics

Metric	FY 2025 Jun 30, 2025 20-F ↗	FY 2024 Jun 30, 2024 20-F ↗	FY 2023 Jun 30, 2023 20-F ↗	FY 2022 Jun 30, 2022 20-F ↗	FY 2021 Jun 30, 2021 20-F ↗	FY 2020 Jun 30, 2020 20-F ↗	FY 2019 Jun 30, 2019 20-F ↗	FY 2018 Jun 30, 2018 20-F ↗
Basic EPS, GAAP (USD)	$-0.72	$-0.87	$0.45	$0.58	$0.13	—	—	—
Free Cash Flow per Share (USD)	$-0.01	$-0.01	$-0.38	$-0.47	$-0.08	—	—	—
Book Value per Share (USD)	$0.01	$0.02	$0.92	$1.31	$-0.40	$-0.27	—	—
Tangible Book Value per Share (USD)	$0.01	$0.02	$0.92	$1.31	$-0.40	$-0.27	—	—
Basic Weighted Avg Shares (shares)	494.49M	494.49M	13.01M	12.81M	10.00M	0	0	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Jun 30, 2025 20-F ↗	FY 2024 Jun 30, 2024 20-F ↗	FY 2023 Jun 30, 2023 20-F ↗	FY 2022 Jun 30, 2022 20-F ↗	FY 2021 Jun 30, 2021 20-F ↗	FY 2020 Jun 30, 2020 20-F ↗	FY 2019 Jun 30, 2019 20-F ↗	FY 2018 Jun 30, 2018 20-F ↗
Working Capital (USD)	$4.24M	$7.92M	$11.01M	$15.87M	$-4.27M	$-2.78M	—	—
Total Equity (USD)	$4.86M	$8.22M	$12.03M	$17.07M	$-4.00M	$-2.65M	$-1.84M	$-1.45M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Jun 30, 2025 20-F ↗	FY 2024 Jun 30, 2024 20-F ↗	FY 2023 Jun 30, 2023 20-F ↗	FY 2022 Jun 30, 2022 20-F ↗	FY 2021 Jun 30, 2021 20-F ↗	FY 2020 Jun 30, 2020 20-F ↗	FY 2019 Jun 30, 2019 20-F ↗	FY 2018 Jun 30, 2018 20-F ↗
Depreciation Expense (USD)	$77.69K	$305.78K	$293.13K	$150.15K	$26.46K	$9.52K	—	—
Net Income, GAAP (USD)	$-3.58M	$-4.30M	$-5.87M	$-7.45M	$-1.35M	$-812.37K	$-390.99K	—
Operating Cash Flow (USD)	$-3.11M	$-4.00M	$-4.96M	$-5.27M	$-767.31K	$-726.57K	$-390.99K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 8 quarters

Regencell Bioscience Holdings Ltd

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RGC with peers